{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:06:28Z","timestamp":1781165188078,"version":"3.54.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40261-021-01048-z","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T12:03:01Z","timestamp":1623672181000},"page":"663-664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Blister-Packing of 2 mg Buprenorphine Monoproduct as a Patient-Centered Method of Microdosing for Buprenorphine Induction"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9475-760X","authenticated-orcid":false,"given":"Anthony J.","family":"Accurso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"5","key":"1048_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","volume":"41","author":"JP De Aquino","year":"2021","unstructured":"De Aquino JP, Parida S, Sofuoglu M. The pharmacology of buprenorphine microinduction for opioid use disorder. Clin Drug Investig. 2021;41(5):425\u201336. https:\/\/doi.org\/10.1007\/s40261-021-01032-7.","journal-title":"Clin Drug Investig"},{"key":"1048_CR2","doi-asserted-by":"publisher","unstructured":"Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of buprenorphine\/naloxone: a review of the literature. Am J Addict. https:\/\/doi.org\/10.1111\/ajad.13135(Epub 30 Dec 2020).","DOI":"10.1111\/ajad.13135"},{"issue":"5","key":"1048_CR3","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.1097\/ADM.0000000000000618","volume":"14","author":"JP De Aquino","year":"2020","unstructured":"De Aquino JP, Fairgrieve C, Klaire S, Garcia-Vassallo G. Rapid transition from methadone to buprenorphine utilizing a micro-dosing protocol in the outpatient veteran affairs setting. J Addict Med. 2020;14(5):e271\u20133.","journal-title":"J Addict Med"},{"issue":"3","key":"1048_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/ADM.0000000000000745","volume":"15","author":"MB Weimer","year":"2021","unstructured":"Weimer MB, Guerra M, Morrow G, Adams K. Hospital-based buprenorphine micro-dose initiation. J Addict Med. 2021;15(3):255\u20137.","journal-title":"J Addict Med"},{"key":"1048_CR5","doi-asserted-by":"publisher","unstructured":"Thakrar AP, Jablonski L, Ratner J, Rastegar DA. Micro-dosing intravenous buprenorphine to rapidly transition from full opioid agonists. J Addict Med. https:\/\/doi.org\/10.1097\/ADM.0000000000000838(Epub 19 Mar 2021).","DOI":"10.1097\/ADM.0000000000000838"},{"issue":"1","key":"1048_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13722-021-00220-2","volume":"16","author":"JSH Wong","year":"2021","unstructured":"Wong JSH, Nikoo M, Westenberg JN, et al. Comparing rapid micro-induction and standard induction of buprenorphine\/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract. 2021;16(1):11. https:\/\/doi.org\/10.1186\/s13722-021-00220-2.","journal-title":"Addict Sci Clin Pract"},{"key":"1048_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/SAR.S109919","volume":"7","author":"R H\u00e4mmig","year":"2016","unstructured":"H\u00e4mmig R, Kemter A, Strasser J, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99\u2013105.","journal-title":"Subst Abuse Rehabil."},{"key":"1048_CR8","doi-asserted-by":"publisher","first-page":"108147","DOI":"10.1016\/j.drugalcdep.2020.108147","volume":"214","author":"AS Huhn","year":"2020","unstructured":"Huhn AS, Hobelmann JG, Oyler GA, Strain EC. Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug Alcohol Depend. 2020;214:108147.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"1048_CR9","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1503\/cmaj.74018","volume":"192","author":"PA Randhawa","year":"2020","unstructured":"Randhawa PA, Brar R, Nolan S. Buprenorphine-naloxone, \u201cmicrodosing\u201d: an alternative induction approach for the treatment of opioid use disorder in the wake of North America\u2019s increasingly potent illicit drug market. CMAJ. 2020;192(3):E73.","journal-title":"CMAJ"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-021-01048-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-021-01048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T18:35:13Z","timestamp":1625078113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-021-01048-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":9,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1048"],"URL":"https:\/\/doi.org\/10.1007\/s40261-021-01048-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]},"assertion":[{"value":"26 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to prepare this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anthony J. Accurso has no conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}